Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma

NCT02720484 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02720484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02720484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Terminated
Start date
March 30, 2016
Completion date
November 2, 2018
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic carcinoma in the adrenal cortex, recurrent adrenal cortex carcinoma, stage iii adrenal cortex carcinoma, stage iv adrenal cortex carcinoma